take stock like lower open maintain hold
view edward quarter updat mix headlin
number suggest given view expect high go
quarter judg stock rel ytd perform premium valuat
believ like translat lower stock upon open ew share
one best perform med-tech stock year use
last night close versu attribut
perform improv expect around transcathet valv busi
heel better expect result report februari howev
report rst quarter transcathet valv miss expect
reason expect stock come pressur upon market
open would buyer weak believ like
remain skeptic transcathet valv outlook may keep
stock range-bound near intermedi term maintain hold
rate price target
takeaway quarter call mix headlin
result mix headlin number suggest sale
million report basi million adjust basi
latter came factset fs consensu
estim result within compani guidanc rang
upsid rel consensu due stronger
adjust surgic heart valv critic care sale transcathet valv
sale came expect vs respect total
underli sale deceler
pace adjust cash ep ahead
consensu dbe high end
manag note upsid function delay
invest spend favor fx greater benet stock
guidanc updat mix view second quarter
edward expect sale billion rang bracket
consensu million adjust ep
street consensu full year manag reiter
sale target higher end billion rang versu
consensu rais ep guidanc versu
prior versu consensu chang
price apr usd
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
guidanc reect lower tax rate versu
prior fx also invest rais
ep estim though ep
unchang
transcathet valv trend mix ew lost share europ
tavr sale came million street consensu estim
million believ market expect like
beat quarter tavr sale oper quarter
deceler rate manag
comment us procedur growth mid-teen
believ line market receiv
lower royalti due predetermin
step-down royalti rate intern edward note procedur
growth low doubl digit believ lost share
europ manag comment premium price
centera self-expand transcathet aortic valv launch europ
limit impact quarter edward reiter full year
transcathet valv guidanc high end rang
expect improv competit posit continu eu roll-
centera forthcom launch sapien ultra
plu benet approv continu access protocol us
rearm transcathet mitral valv sale target approxim
million year despit record less million sale
clinic trial updat edward receiv approv begin clinic
trial centera expect commenc
slightli earlier expect single-arm trial includ
intermedi risk patient posit view intermedi
year clinic follow-up end point also posit
respect sapien ultra system manag note
conduct small trial support ce mark european approv
anticip approv continu believ approv
us late addit studi need
respect harpoon medic devic manag ag
could risk european launch evalu
complic patient studi trial eort
transcathet mitral tricuspid continu edward data
expect europcr meet may
forecast ratio
takeawaysvari analysi underli ep surpris compani data deutsch bank factsetsourc compani data deutsch bank factset product sale trend mrptdunderlyingsurg thv thv revenu guidanc versu consensu ep rang guidanc fs consensu reiter full year sale guidanc higher end previou rang versu consensu ep guidanc rais versu previou rang tax rate expect versu prior includ germani stock sale shv consign convers within guidanc rang factset consensu fs deutsch bank estim dbe underli sale growth adjust ep fs dbe addit detail quarter million except per share data chang sale constant currenc basi unless otherwis note posit reiter sale guidanc increas adjust cash ep guidanc stonger expect surgic heart valv critic care manag note us tavr strength particularli strong low volum ew announc receiv approv centera trial intermedi risk patientsmix tavr sale miss consensu dbe due competit pressur european excess tax benefit fx delay spend lead less clean earn beatquick double-digit procedur growth ou mid-teen compani reiter expect underli sale growth higher end profit sg margin improv attribut time expens program spend centera trial exclud special item tax rate share count y/i adjust ep y/i guidanceful year april
note y/i chang underli adjust basi unless note
transcathet heart valv therapi thvt valv adjust sale
million factset million dbe million sale
y/i underli basi repres deceler
growth rate growth edward continu
expect thvt sale high end
underli growth billion sale guidanc rang
surgic heart valv therapi sale million report basi
million adjust basi latter ahead factset
million dbe million sale underli
basi driven favor mix higher new product
anticip sale return adjust reect convers
consign inventori model quarter believ one
look adjust result -- report -- compar
consensu expect manag reiter guidanc full
year expect surgic heart valv therapi high end
critic sale million factset
million dbe million manag comment
result driven strong growth across portfolio led
hemospher advanc monitor platform strong region
perform asia pacic manag
continu expect sale come high end
incom statementtot good expens inc incom incom dilut adjust adjust epsamort litig expens exclud ip litig exp ep ip changesal incom april
